- Market Realist•4 hours ago
Celgene (CELG) has a comprehensive strategy to target patient segments with unmet demands. It's expected to continue to dominate the multiple myeloma space in 2017.
- Market Realist•5 hours ago
According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.
- Motley Fool•6 hours ago
These three biotech stocks look poised to outperform.
CELG : Summary for Celgene Corporation - Yahoo Finance
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||112.31 x 200|
|Ask||112.49 x 100|
|Day's Range||111.63 - 113.36|
|52 Week Range||93.05 - 127.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||42.65|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|